DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
CagriSema combines cagrilintide (amylin analog) with semaglutide. REDEFINE-1 showed ~22.7% weight loss at 68 weeks — strong, though below the ~25% Novo had guided.
Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying through a different pathway than GLP-1. Cagrilintide (long-acting amylin analog) plus semaglutide creates dual satiety signaling. The combination targets appetite through two complementary mechanisms.
Versus Wegovy (semaglutide alone, ~15%): CagriSema adds ~7-8 percentage points. Versus Zepbound (~21%): roughly comparable. The REDEFINE-1 readout underperformed Novo guidance, which dampened investor expectations, but the efficacy is still category-leading.
REDEFINE Phase 3 program readouts 2024-2025. FDA filing expected 2026, approval 2026-2027. Will be Novo’s flagship response to tirzepatide dominance.
Semaglutide responders who want more efficacy without switching molecule class entirely. Amylin co-agonism is a genuinely new mechanism for most patients.
Editorial summary of investigational drugs not yet FDA-approved. Trial data and timelines change. Not medical advice; do not delay current treatment waiting for pipeline agents.